MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
Open Access
- 2 February 2021
- journal article
- research article
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 10 (1) , 1-12
Abstract
Background: Acute myeloid leukemia (AML) with the t(8;21)(q22;q22) chromosomal translocation is among the most common subtypes of AML and produces the AML1-ETO (RUNX1-ETO, RUNX1-RUNX1T1) oncogenic fusion gene. AML1-ETO functions as an aberrant transcription factor which plays a key role in blocking normal hematopoiesis. Thus, the expression of AML1-ETO is critical to t(8;21) AML leukemogenesis and maintenance. Post-transcriptional regulation of gene expression is often mediated through interactions between trans-factors and cis-elements within transcript 3′-untranslated regions (UTR). AML1-ETO uses the 3′UTR of the ETO gene, which is not normally expressed in hematopoietic cells. Therefore, the mechanisms regulating AML1-ETO expression via the 3’UTR are attractive therapeutic targets. Methods: We used RNA-sequencing of t(8;21) patients and cell lines to examine the 3′UTR isoforms used by AML1-ETO transcripts. Using luciferase assay approaches, we test the relative contribution of 3′UTR cis elements to AML1-ETO expression. We further use let-7b microRNA mimics and anti-let-7b sponges for functional studies of t(8;21) AML cell lines. Results: In this study, we examine the regulation of AML1-ETO via the 3’UTR. We demonstrate that AML1-ETO transcripts primarily use a 3.7 kb isoform of the ETO 3′UTR in both t(8;21) patients and cell lines. We identify a negative regulatory element within the AML1-ETO 3′UTR. We further demonstrate that the let-7b microRNA directly represses AML1-ETO through this site. Finally, we find that let-7b inhibits the proliferation of t(8;21) AML cell lines, rescues expression of AML1-ETO target genes, and promotes differentiation. Conclusions: AML1-ETO is post-transcriptionally regulated by let-7b, which contributes to the leukemic phenotype of t(8;21) AML and may be important for t(8;21) leukemogenesis and maintenance.Keywords
Funding Information
- National Cancer Institute (R01CA104509)
- National Cancer Institute (F31CA228324)
- National Cancer Institute (T32CA009523)
This publication has 71 references indexed in Scilit:
- The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signalingBlood Cancer Journal, 2020
- Restoring Let-7 microRNA Biogenesis Using a Small-Molecule Inhibitor of the Protein–RNA InteractionACS Medicinal Chemistry Letters, 2018
- Regulation by 3′-Untranslated RegionsAnnual Review of Genetics, 2017
- MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging conceptsBlood, 2017
- Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expressionGene, 2017
- An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cellsOncotarget, 2017
- MicroRNA biogenesis pathways in cancerNature Reviews Cancer, 2015
- HISAT: a fast spliced aligner with low memory requirementsNature Methods, 2015
- Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-RenewalCell Reports, 2014
- MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growthCell Research, 2008